Indivior (NASDAQ:INDV) Upgraded by RODMAN&RENSHAW to Strong-Buy Rating

Indivior (NASDAQ:INDV) was upgraded by research analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Craig Hallum reduced their price target on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, October 11th. Rodman & Renshaw assumed coverage on shares of Indivior in a research note on Tuesday. They set a “buy” rating and a $16.00 price objective for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $16.00 target price (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th.

Indivior Stock Down 0.6 %

INDV stock opened at $12.15 on Tuesday. The business’s 50-day moving average price is $11.72 and its 200-day moving average price is $11.01. The stock has a market cap of $1.68 billion, a P/E ratio of -303.67 and a beta of 0.74. Indivior has a twelve month low of $7.33 and a twelve month high of $23.22.

Hedge Funds Weigh In On Indivior

Several institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Indivior during the fourth quarter valued at about $56,000. Stifel Financial Corp acquired a new position in Indivior in the 3rd quarter worth approximately $100,000. Melqart Asset Management UK Ltd purchased a new position in shares of Indivior during the third quarter worth $132,000. Jane Street Group LLC purchased a new position in shares of Indivior during the 3rd quarter valued at about $180,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Indivior in the third quarter valued at approximately $294,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.